Immune Checkpoint Inhibitor

CHICAGO — Patients and prescribers should be more aware of the potential for major adverse cardiac events after immune checkpoint inhibitor-based therapy, according to retrospective study results presented at ASCO Annual Meeting.

The FDA approved nivolumab plus fluoropyrimidine- and platinum-containing chemotherapy and nivolumab plus ipilimumab as first-line treatments for adults with unresectable advanced or metastatic esophageal squamous cell carcinoma.

Nivolumab plus ipilimumab failed to extend OS compared with standard first-line chemotherapy for patients with unresctable or metastatic urothelial carcinoma whose tumor cells expressed PD-L1 at 1% or greater.

A randomized phase 3 trial designed to evaluate tiragolumab plus atezolizumab for certain patients with advanced lung cancer failed to meet its co-primary endpoint of PFS, topline data showed.

The FDA granted priority review to durvalumab plus chemotherapy for treatment of locally advanced or metastatic biliary tract cancer.

DALLAS — Multiple factors predicted improved survival among patients with head and neck or salivary gland cancers treated with pembrolizumab plus vorinostat, according to prospective study results.

Men, smokers and younger patients with non-small cell lung cancer all appeared to derive more benefit from immunotherapy, according to a systematic review published in JNCI Cancer Spectrum.

A novel PD-1/CTLA-4 bispecific checkpoint inhibitor demonstrated antitumor activity and tolerability among patients with advanced solid tumors, according to study results.

The FDA granted orphan drug designation to serplulimab for treatment of small cell lung cancer.

Patients with non-small cell lung cancer and an exceptionally high anti-PD-1 therapy response more frequently had a variant of the CTLA-4 gene, which may be used to identify those who may benefit from such treatment.